Body
recently ran a story about Relyvrio — a new medication for treatment of amyotrophic lateral sclerosis (ALS) — that included insights from Colin Franz, MD, PhD, physician-scientist and director, Electrodiagnostic Laboratory, Shirley Ryan 嫩B研究院.
In addition to his roles at Shirley Ryan 嫩B研究院, Dr. Franz is a physician for the Les Turner ALS Center at Northwestern Medicine.
Dr. Franz discussed the decision by the U.S. Food and Drug Administration (FDA) to approve Relyvrio after one successful clinical trial — generally, two successful trials are required before FDA approval.
“There’s a risk of being too cautious with allowing drugs to get to patients when you have a disease that’s as devastating [as ALS],” said Dr. Franz “It’s exciting and we’re very cautiously optimistic that this is going to help our patients.”